Growth Hormone Deficiency News and Research

RSS

FDA grants IND for AEZS-130 Phase 2A trial in cancer cachexia

Aeterna Zentaris Inc. today announced that the U.S. Food and Drug Administration has granted Jose M. Garcia, MD, PhD, Assistant Professor, Division of Diabetes Endocrinology and Metabolism, Departments of Medicine and Molecular and Cell Biology, Baylor College of Medicine and Michael I. DeBakey Veterans Administration Medical Center, in Houston Texas, an Investigational New Drug approval for the initiation of a Phase 2A trial to assess the safety and efficacy of repeated doses of the Company's ghrelin agonist, AEZS-130, in patients with cancer cachexia.

28 Nov 2011

Favorable top-line results from Aeterna Zentaris' AEZS-130 Phase 3 study on AGHD

Aeterna Zentaris Inc. today announced favorable top-line results of its completed Phase 3 study with AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency.

31 Aug 2011

Israeli OCS approves $1.7M grant to support PROLOR's hGH-CTP program

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the Israeli Office of the Chief Scientist (OCS) has approved a 2011 grant to PROLOR's Israeli-based R&D subsidiary for the company's development program for hGH-CTP, its long-acting version of human growth hormone.

10 Aug 2011

Positive results from hGH-CTP Phase II trial in growth hormone deficient adults

PROLOR Biotech, Inc. today reported positive results from a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone (hGH-CTP) in growth hormone deficient adults.

4 Aug 2011

Aeterna Zentaris completes AEZS-130 Phase 3 study for diagnosis of AGHD

Aeterna Zentaris Inc. today announced completion of its Phase 3 study with AEZS-130 as the first oral diagnostic test for Adult Growth Hormone Deficiency (AGHD).

27 Jul 2011

Positive interim results from PROLOR's hGH-CTP Phase II trial in growth hormone deficiency

PROLOR Biotech, Inc. today reported positive interim efficacy results from a Phase II clinical trial of its long-acting CTP-modified version of human growth hormone in growth hormone deficient adults.

11 Apr 2011

Girls with medical conditions causing short stature go undiagnosed

Primary care doctors are less likely to refer short girls than short boys for diagnostic testing that can reveal underlying medical reasons for their short stature, according to a new study of an urban pediatric population in Philadelphia. Girls with medical conditions causing their short stature may go undiagnosed, or may be diagnosed later than boys, limiting timely treatment.

21 Mar 2011

Aeterna Zentaris reaches agreement with FDA for Solorel SPA as a diagnostic test in AGHD

Aeterna Zentaris Inc. today announced that it has reached agreement with the Food and Drug Administration (FDA) on a Special Protocol Assessment (SPA) for Solorel® (AEZS-130, macimorelin) which will enable the Company to complete the ongoing registration study required to gain approval as a diagnostic test for Adult Growth Hormone Deficiency (AGHD).

20 Dec 2010

Aeterna Zentaris' AEZS-130 demonstrates potential as oral diagnostic test for AGHD

Aeterna Zentaris Inc., today announced that an interim review of a Phase 3 trial of AEZS-130 (macimorelin, SolorelTM), demonstrates the compound may provide a simple, well-tolerated and safe oral diagnostic test for Adult Growth Hormone Deficiency (AGHD). The data was presented earlier today by Beverly M.K. Biller, M.D. of the Harvard Medical School/Massachusetts General Hospital in Boston, at the 5th International Congress of the Growth Hormone Research Society (GRS) and the Insulin-like Growth Factors (IGF) Society in New York City.

6 Oct 2010

FDA grants orphan drug designation to hGH-CTP for treating growth hormone deficiency

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to hGH-CTP, PROLOR's longer-acting version of human growth hormone for the treatment of growth hormone deficiency.

5 Oct 2010

Human growth hormone can treat cystic fibrosis symptoms

Human growth hormone can be used successfully to treat some symptoms of cystic fibrosis, but its impact on the disease itself remains unknown, according to a new report funded by HHS' Agency for Healthcare Research and Quality (AHRQ).

5 Oct 2010

Researchers recommend traumatic brain injury reclassification for additional funding

Traumatic brain injury, currently considered a singular event by the insurance industry and many health care providers, is instead the beginning of an ongoing process that impacts multiple organ systems and may cause or accelerate other diseases and disorders that can reduce life expectancy, according to research from the University of Texas Medical Branch at Galveston.

27 Aug 2010

FDA clears PROLOR Biotech's Phase II clinical trial of hGH-CTP

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced that it has received regulatory clearance from the U.S. Food and Drug Administration (FDA) to conduct a Phase II clinical trial in the U.S. of its longer-acting version of human growth hormone, hGH-CTP.

24 Aug 2010

SynCo Bio Partners extends collaboration with Versartis

SynCo Bio Partners today announced an extension of its successful collaboration with Versartis, Inc. following the recent initiation of a Phase 1 clinical trial in type 2 diabetes mellitus (T2DM) patients with monthly dosing of VRS-859. This news comes less than 12 months since the parties entered into a strategic partnership to manufacture Versartis' lead product VRS-859 (exenatide-XTEN).

30 Jul 2010

PROLOR Biotech initiates Phase II clinical trial of biobetter version of human growth hormone

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today announced initiation of a Phase II clinical trial of hGH-CTP, the company's proprietary biobetter version of human growth hormone (hGH).

21 Jul 2010

Positive preclinical data on Aeterna Zentaris' AEZS-130/Ghrelin Receptor Agonist presented at ENDO meeting

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that a poster on its oral synthetic growth hormone secretagogue/ghrelin receptor agonist, AEZS-130, was presented yesterday at the 92nd Annual Endocrine Society (ENDO) Meeting and Expo, which is held through June 22, 2010 at the San Diego Convention Center in San Diego, California.

21 Jun 2010

Aeterna Zentaris to present poster on AEZS-130 growth hormone secretagogue/ghrelin receptor agonist at 92nd ENDO

Aeterna Zentaris Inc. a late-stage drug development company specialized in oncology and endocrine therapy, today announced that a poster on its oral synthetic growth hormone secretagogue/ghrelin receptor agonist, AEZS-130, will be presented at the upcoming 92nd Annual Endocrine Society (ENDO) Meeting and Expo, which will be held June 19 through 22, 2010 at the San Diego Convention Center in San Diego, California.

15 Jun 2010

Australian researchers show positive effect of growth hormone on athletic performance

Australian researchers have published the results of a study, for the first time showing a positive effect of growth hormone on athletic performance.

5 May 2010

Æterna Zentaris announces 2009 financial and operating results

Æterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today reported financial and operating results as at and for the fourth quarter and the full year ended December 31, 2009.

24 Mar 2010

New resources to support Teva Pharmaceutical Industries' Tjet injector system now available

Teva Pharmaceutical Industries Ltd. announced today the availability of new resources to support the recently introduced Tjet® injector system, a needle-free device designed to deliver Teva’s TEV-TROPIN® [somatropin (rDNA origin) for injection] brand human growth hormone (hGH) to children who have growth failure due to inadequate secretion of normal endogenous growth hormone.

3 Feb 2010